Table 6 Items included in the questionnaire and results
| Â | Â | Mean | Median | Interquartile range | Above the median | Result |
|---|---|---|---|---|---|---|
51 | Treatment of rhinitis in patients with asthma contributes to the improvement of bronchial symptoms | 7.7 | 8 | 2 | 7.5 | Agreement |
52 | Treatment of rhinitis in patients with asthma reduces socio-economic costs | 7.93 | 8 | 1.5 | 12.5 | Agreement |
53 | Treatment of rhinitis in patients with asthma improves their quality of life | 8.33 | 8.5 | 1 | 2.5 | Agreement |
54 | Allergen avoidance in ARD is the first line of treatment for all patients, regardless of severity | 7.8 | 8 | 2 | 12.5 | Agreement |
55 | Maintenance drug therapy must be recommended, at least as long as the patient is exposed to the causative airborne allergen | 7.35 | 8 | 2 | 22.5 | Agreement |
56 | Maintenance drug therapy can be extended for as long as is necessary to achieve good control of the disease | 8.38 | 9 | 1 | 0 | Agreement |
57 | Adjustment of treatment in ARD patients must consider the “maximum severity reached in previous allergenic exposures” | 7.28 | 8 | 1 | 15 | Agreement |
58 | Treatment of patients who experienced severe symptoms in previous allergenic exposures may not follow the step-up strategy recommended by consensus guidelines and can begin with a higher therapeutic step | 7.85 | 8 | 2 | 7.5 | Agreement |
59 | The doses used in the pharmacological treatment of ARD patients may be greater than those commonly used in non-allergic patients | 6.23 | 7 | 3 | 42.5 | No consensus |
60 | The prognosis of ARD depends on the presence of polysensitization | 6.6 | 7 | 2 | 30 | Agreement |
61 | The treatment strategy in polysensitized patients consists of adapting maintenance treatment to the relevant allergen | 6.95 | 7 | 1 | 22.5 | Agreement |
62 | Failure of drug therapy is not a prerequisite for AIT in patients with ARD | 8.35 | 9 | 1 | 2.5 | Agreement |
63 | AIT is most effective in early stages of ARD | 7.95 | 8 | 1.5 | 10 | Agreement |
64 | Most patients will benefit from treatment with AIT to slow disease progression | 7.75 | 8 | 2 | 15 | Agreement |
65 | Most patients with ARD will benefit from treatment with AIT to reduce the severity of symptoms and use of medication and to improve quality of life | 7.95 | 8 | 1.5 | 7.5 | Agreement |
66 | Unlike pharmacological treatment, AIT improves the prognosis of ARD | 8.08 | 8 | 1 | 5 | Agreement |
67 | AIT decreases the occurrence of new sensitizations in ARD patients | 6.53 | 7 | 3 | 37.5 | No consensus |
68 | AIT can prevent the development of bronchial symptoms in patients with rhinoconjunctivitis | 7.85 | 8 | 2 | 10 | Agreement |
69 | In ARD patients, identification of the airborne allergen that is clinically responsible for symptoms is essential when attempting to establish the indication of AIT | 8.7 | 9 | 0.5 | 0 | Agreement |
70 | The composition of immunotherapy in polysensitized ARD patients must be based on a selection of the relevant allergen(s) according to the patient’s clinical and sensitization profile | 8.3 | 9 | 1 | 2.5 | Agreement |
71 | A sufficient dose of each allergen must be ensured in AIT with mixtures of allergens in polysensitized ARD patients | 8.23 | 8.5 | 1 | 5 | Agreement |